• DKSH expands its collaboration with Healthium Medtech to distribute its high-quality surgical products to clinics and hospitals across the region.

December, 2021

DKSH Business Unit Healthcare, Asia’s leading partner for healthcare companies seeking to grow their business in Asia, has expanded its partnership with Healthium MedtechPvt Ltd., a global leader and Innovator in medical devices.The Healthium Group is the world’s fourth largest surgical suture manufacturer and the largest surgical suture needle maker by volume, exporting to over 70 countries.After signing an agreement in Myanmar this October, DKSH and Healthium have now ex-tended their partnership to also include Thailand, Cambodia and Laos where DKSH will offer full-agency service, manage distribution and commercialize Healthium’s products.The agreement is in line with DKSH's strategy of expanding into higher value-added segments and services such as medical devices.

The Healthium Group has a lineage of 36 years in creating precision based medical devices across the world. Its products are used in 1 in 6 surgeries globally. Healthium is the largest domestic medtech brand and the largest exporter of surgical sutures from India.

As a partner, DKSH can help Healthium deliver a strong market entry across Asia, particularly Thailand, Cambodia, Laos and Myanmar. Healthium can quickly build its brand and gain market share by tapping into DKSH’s extensive and experienced sales force and marketing and distribution channels to ensure that their products reach extensively to hospitals, clinics, and medical channels across the country and also achieve Healthium’s vision of “Access to precision Medtechfor every patient, globally”.

Anish Bafna, CEO & MD Healthium Group, said: “We are delighted to extend our partnership with DKSH in Thailand, Cambodia, Laos and Myanmar. Our products are manufactured to global standards with USFDA and CE approvals, with acceptance in over 70 countries. It is our vision to provide access to precision medtech for every patient, globally and we look forward to leverage DKSH’s extensive reach, quality of operations and scale to touch clinics and hospitals in the Region with our precision medtech products that bring patient safety and better outcomes to the fore”

Bijay Singh, Global Head of Business Unit Healthcare, DKSH, commented: “The extended partnership with Healthium demonstrates our commitment to bringing high-quality medical products to Asian pa-tients and enriching their lives. This collaboration will not only show another milestone in expanding our portfolio, but alsostrengthen our goal to become the preferred partner for hospitals for medical devices. Through working with Healthium, we are proud toimprove access tohigh-quality sutures for all hospitals and clinics in the region, whilecommittingto driving growth for our partnerin delivering their innovative and high-quality products.”

About Healthium Medtech
Healthium Medtech is present in over 70 countries, covers 18,000+ hospitals across India and has a workforce of 1,500 employees of which 60% are women. Its portfolio includes Minimally Invasive Arth-roscopy implants and Endoscopy staplers and cutters, a full range of Absorbable, Non-Absorbable and Specialty Surgical Sutures, Wound Closure products including Hernia Meshes, Skin Staplers, Cardiac Pacing Wires and Hemostats. Healthium has six Manufacturing facilities across India and the UAE and the Company holds over 55patents in India and the U.S, including those applied for. Backed by stringent R & D norms, the Company’s products adhere to the highest global quality standards, having accreditations and approvals from 510K (USFDA), CE & ISO.

About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCom-merce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Ex-change, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and overt-the-counter (OTC) products as well as medical devices. With around 8,220 specialists, the Business Unit generated net sales of CHF 6.0 billion in 2019.

For further information, please contact:

DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Communications
+66 2 220 9739
sheena.flannery@dksh.com

HEALTHIUM MEDTECH LTD

(formerly known as Healthium Medtech Private Limited)

472/D, 13th Cross, 4th Phase, Peenya Industrial Area, Peenya Industrial Area Phase IV, Peenya, Bengaluru, Karnataka - 560 058, INDIA

CIN: U03311KA1992PLC013831

contact@healthiummedtech.com

For any queries or complaints write to
care@healthiummedtech.com

Customer care number
+91-80-41868000

DISCLAIMER

“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”

We use cookies to ensure you get the best experience on our website. Click here to view cookie policy